Recent studies have highlighted a potential link between certain progesterone-based medications and an increased risk of meningiomas, which are typically benign brain tumors. While these tumors are more common in women and often asymptomatic, some high-dose progestogens—such as medroxyprogesterone acetate (found in Depo-Provera), cyproterone acetate (found in Dianette), and nomegestrol acetate (found in Zoely)—have been associated with a higher risk of developing meningiomas. Notably, the risk appears to be dose-dependent, with prolonged use increasing the likelihood of tumor development. It's important to note that while these associations exist, the overall risk remains low, and more research is needed to fully understand the relationship between progesterone use and meningioma development. Women using these medications should consult with their healthcare providers to discuss potential risks and consider alternative options if necessary.